NCT03401788 - A Phase 2 Study of Belzutifan (PT2977, MK-6482) for the Treatment of Von Hippel Lindau (VHL) Disease-Associated Renal Cell Carcinoma (RCC) (MK-6482-004) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 2, 2018

Primary Completion Date

March 29, 2026

Study Completion Date

March 29, 2026

Conditions

VHL - Von Hippel-Lindau SyndromeVHL Gene MutationVHL SyndromeVHL Gene InactivationVHL-Associated Renal Cell CarcinomaVHL-Associated Clear Cell Renal Cell Carcinoma

Interventions

DRUG

Belzutifan

120 mg once daily (three 40 mg oral tablets once daily).

Trial Locations (11)

15232

University of Pittsburgh Medical Center, Pittsburgh

19104

University of Pennsylvania Medical Center, Philadelphia

20892

National Institutes of Health Clinical Center, Bethesda

37232

Vanderbilt Medical Center, Nashville

48109

University of Michigan, Ann Arbor

77030

MD Anderson Cancer Center, Houston

84112

Huntsman Cancer Institute, Salt Lake City

02114

Massachusetts General Hospital, Boston

Unknown

Aarhus University Hospital, Aarhus

Hospital Georges Pompidou, Paris

Cambridge University Hospital, Cambridge

All Listed Sponsors

lead

Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

INDUSTRY